METHYLPREDNISOLONE SODIUM SUCCINATE

Post-LOE

methylprednisolone sodium succinate

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Feb 1980

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METHYLPREDNISOLONE SODIUM SUCCINATE (methylprednisolone sodium succinate) by Bristol Myers Squibb is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, temporal arteritis, polymyositis and 15 more indications. First approved in 1980.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…

Indications (18)

dermatomyositis

Worked on METHYLPREDNISOLONE SODIUM SUCCINATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.